Effects of glycogen synthase kinase inhibitor on gliblastoma multiforme cell line via apoptosis and cell signaling pathways

Introduction: Glioblastoma multiforme is known as the most common and agressive primary brain tumor that approximately 9000 new people are diagnosed every year over the world (1). Grade IV/V types of gliomas are known as glioblastoma multiforme. Despite the totally surgical procedure and following chemoradiotherapy, patients diagnosed with glioblastoma survive less than 24 months and the recurrence of the tumour is almost a rule (2). This failure in treatment, has led researchers to understand the molecular pathogenesis of the disease and cellular signaling pathways Materials and methods: GSK3 inhibition of GBM cell lines planned and the results of this inhibition to the apoptosis process via epidermal growth factor Receptor (EGFR) and nuclear factor kappa Beta (NF-κB) are studied. Glioblastoma (U-87 mg) and normal brain (SVGp12) cell lines used and said pathways were subjected to immunofluorescence analysis and cell viability tests. Results: With the use of GSK3 inhibitor on GBM cell line results as decreased expression of NF-κB. Although increased apoptosis has been shown both brain cell line and GBM cell line with the addition of GSK3 inhibitor. Conclusion: With the help of this study, a common malignant brain tumor that could not be taken too much way about the kind of treatment, light is shed on the literature to investigate the potential therapeutic model that would inactivate the level of cellular signaling pathways.